Roxithromycin is a new macrolide antibiotic with good absorption and a longer half-life than erythromycin. Worldwide clinical studies to evaluate its efficacy and safety in the treatment of infections of the lower respiratory tract have achieved a clinical success rate of 89% with few and mild side effects.
Introduction
Macrolides have proved to be extremely nontoxic antibiotics with good activity against such common respiratory pathogens as streptococci, many Haemophilus species, and Legionella species (Pasculle et al., 1981; Gribble & Chow, 1982) . Despite the good antibacterial spectrum of these agents, their pharmacokinetic properties are not ideal because of the relatively short half-lives. Roxithromycin is a new macrolide antibiotic with superior pharmacokinetics. An ether oxime derivative of erythromycin, roxithromycin has a spectrum of activity similar to that of erythromycin (Jones, Barry & Thornsberry, 1983; Barlam & Neu, 1984; Rolston, LeBlanc & Ho, 1985) along with good gastrointestinal absorption and an extended half-life (Tremblay et al., 1985) .
In view of roxithromycin's antibacterial spectrum and pharmacokinetic properties, the antibiotic appears to offer advantages in the treatment of infections of the lower respiratory tract. Studies evaluating its efficacy and safety have been conducted in the United States, Europe, South America, and South Africa. This paper presents an overview of these studies as they relate to infections of the lower respiratory tract and then describes in greater detail a double-blind study comparing roxithromycin and cephradine in South African gold miners with pneumonia caused by Streptococcus pneumoniae.
Overview of roxithromycin in lower respiratory tract infections
Roxithromycin has been clinically evaluated as an antibiotic for infections of the lower respiratory tract in comparative and noncomparative studies ( Table I) . Assessments of clinical response were made in more than 700 adult patients given a dosage of 150 mg for at least five days. The usual duration of treatment was seven to 15 days, and in exceptional circumstances, treatment was continued for 20 days. Patients were typical of those seen in hospital and outpatient practices.
Despite differences in the study protocols, certain features were common to all the studies. Patients were enrolled who had clinical signs and symptoms of lower respiratory tract infection, confirmed by X-ray evidence of pulmonary infiltration. Bacteriological, X-ray, and clinical laboratory examinations were performed before treatment and within 48 h after treatment was concluded. Pathogens and their sensitivities to the antibiotics used in the respective studies were determined in isolates from blood culture, purulent bronchial secretions, or pleural effusion specimens. If resistance to roxithromycin or the comparative drug was demonstrated, the patient was removed from the study.
Clinical and bacteriological responses were judged to be satisfactory or unsatisfactory. A satisfactory clinical response was characterized by normal body temperature and disappearance of functional, general and clinical signs and symptoms, In all comparative studies, treatments were allocated according to a randomization table. Three of the studies were double-blind comparisons of roxithromycin with other antibiotics used to treat such infections. The roxithromycin-cephradine study is one I shall discuss in the next section. The studies comparing roxithromycin with erythromycin ethylsuccinate or doxycycline used a double-placebo method in which patients ingested both the assigned antibiotic and a placebo matching the alternate drug.
The most common indications for antibiotic therapy in these studies were pneumonia, acute bronchitis in patients with obstructive airways disease, and acute bronchitis. The most frequent pathogens were S. pneumoniae and H. influenzae. A small number of patients had atypical pneumonias caused by Mycoplasma, Chlamydia or Legionella spp. In neither study were statistically significant differences in clinical (Tables I and II) or bacteriological (Table III) responses found between roxithromycin and the comparative antibiotic. Although there were too few patients with atypical pneumonias to permit statistical analysis, it is noteworthy that roxithromycin was 100% clinically effective in five cases of Mycoplasma pneumonia and two cases of Legionnaires' disease.
The U.S. studies yielded too few patients with infections of the lower respiratory tract to permit analyses. Results of the noncomparative trial substantiate the efficacy of roxithromycin observed in comparative trials. Treatment was clinically successful in 93% (208/224) of patients with pneumonia caused by common pathogens, 91% (187/205) of patients with an acute episode of chronic obstructive airways disease, and 100% of 15 patients with atypical pneumonia. Bacteriological success rates were 90% (118/121) in infections caused by S. pneumoniae, 80% (16/20) of those caused by H. influenzae, and 100% in nine infections caused by S. pyogenes.
The incidence of side effects judged possibly or probably related to antibiotic therapy in the foregoing studies ranged from 2% to 14% with roxithromycin and from 3% to 15% with erythromycin ethylsuccinate; it was 5% with doxycycline. Within each study, there were no statistically significant differences between antibiotics with respect to incidence and type of side effects. By far the most frequent side effects were gastrointestinal, including gastric pain, nausea, vomiting, diarrhoea, constipation, flatulence and anorexia.
The results of these studies demonstrate the efficacy and safety of roxithromycin for treatment of infections of the lower respiratory tract. The clinical success rate for all studies combined was 89% when roxithromycin was administered in a dosage of 150 mg bid. Results compared favourably with results of other antibiotics in parallel groups of patients.
Roxithromycin versus cephradine in pneumococcal pneumonia
Pneumonia caused by S. pneumoniae is a serious problem throughout the world. In some populations such as South African gold miners, its annual incidence has been estimated at 200 cases per 1000 population (Austrian, 1974) , contrasted with 2-2 cases per 1000 population in the United States (Sisk & Riegelmun, 1986) . With appropriate oral antibiotics, many patients with mild to moderate pneumonia can avoid hospitalization. As part of worldwide trials to assess the clinical effectiveness and safety of the new macrolide antibiotic roxithromycin, it was compared with cephradine, another accepted therapy (Mogabgab, 1975) .
Methods
Between June 1985 and February 1986, South African gold miners were evaluated for possible pneumonia at the Leslie Williams Memorial Hospital, Carltonville, South Africa. Those who had a clinical history suggestive of the acute onset of pneumonia, a chest X-ray showing a new infiltrate, and a Gram-stained sputum specimen containing fewer than ten epithelial cells and 25 or more polymorphonuclear leucocytes per high power field along with a predominance of Gram-positive cocci, were entered into the study. Patients were excluded if they were hypersensitive to macrolides, cephalosporins, or penicillins; had renal or hepatic impairment; required parenteral therapy for rapidly progressive pneumonia; or had received other antibiotics within the preceding 72 h. All cases of pneumococcal pneumonia were confirmed by isolation of S. pneumoniae from sputum or blood cultures. Cultures were repeated at the end of treatment if patients were able to produce sputum. Aerobic cultures and sensitivity testing were done at the laboratories of the South African Institute of Medical Research. Susceptibility of the isolates to the antimicrobial agents was determined by means of the Kirby-Bauer method, with a 30 \i% cephalosporin class disc and a 30 /ig roxithromycin disc. Minimum inhibitory concentrations (MIC) were determined for all organisms. The MIC breakpoints used for roxithromycin were sensitive <2mg/l and resistant > 16 mg/1. The MIC breakpoints for the cephradine were sensitive < 16 mg/1 and resistant > 32 mg/1.
Patients with mild to moderately severe pneumonia were allocated according to a schedule of random numbers to double-blind treatment with roxithromycin (150 mg bid) or cephradine (1 g bid). Both drugs were administered orally every 12 h for ten days; patients had to have had at least five days of treatment to be considered for the efficacy assessment. Patients were admitted to the hospital for the first four to seven days of treatment, then were discharged to complete therapy as outpatients if their condition was clinically stable. Patients were hospitalized for observation and treatment and to ensure total patient compliance. Under normal circumstances such patients would be managed as outpatients if compliance was assured. In this study, compliance was monitored by review of hospital records of inpatients and was further assured by having nurses go to the home of outpatients to administer the medication. In all cases informed written consent was obtained from the patients, and the approval of the institutional review board for human studies was obtained.
Results
Ninety of the 160 patients had culture-confirmed pneumoccal pneumonia with all tested strains of S. pneumoniae sensitive to both study drugs. Forty-six patients were given roxithromycin and 44 were given cephradine. All of the patients were relatively young, healthy men with no underlying diseases. Patients in the roxithromycin group ranged in age from 18 to 58 years (mean 301) and those in the cephradine group ranged in age from 18 to 55 years (mean 29-8).
Of the 70 patients excluded from the efficacy evaluation, 68 did not have cultures positive for 5. pneumoniae. Most of them were treated with the assigned drug, however, and responded clinically. Hence these patients were included in the safety data. The remaining two patients left the study after giving consent and have been excluded from all evaluations. A satisfactory clinical response was defined as clinical improvement of signs and symptoms and resolution of the lung infiltrate. Three patients treated with roxithromycin did not respond and were withdrawn from the study, whereas no unsatisfactory clinical responses were seen in the cephradine group (Table IV) .
A satisfactory bacteriological response was defined as either a negative follow-up culture for S. pneumoniae or absence of sputum for culture when therapy was completed. An unsatisfactory bacteriological response was a positive culture for S. pneumoniae at the end of therapy. All of the bacteriological failures (Table IV) resulted from isolation of S. penumoniae in sputum cultures; none of these patients had an unsatisfactory clinical response. The five patients who had bacteraemia before treatment had negative blood cultures on follow-up.
Side effects in both groups (Table V) were generally mild, and no patient was withdrawn from the study because of adverse effects. However, one patient in the roxithromycin group died of massive pulmonary haemoptysis. Most of the side effects in both groups were elevations of transaminase values; these were considerably more frequent among patients treated with cephradine than among those treated with roxithromycin. No bleeding or coagulation abnormalities were seen.
Discussion
In double-blind comparisons, roxithromycin has proved to be as effective as erythromycin ethylsuccinate, doxycycline, and cephradine in treating pneumococcal pneumonia and other infections of the lower respiratory tract. The overall clinical response rate observed in world-wide comparative and noncomparative studies was 89% when roxithromycin was given in a dosage of 150 mg bid. The new macrolide antibiotic also demonstrated an excellent safety profile.
In our study in South African gold miners, we observed a surprisingly high persistence of S. pneumoniae in sputum cultures at the end of therapy; 17% among patients treated with roxithromycin and 23% among those treated with cephradine. Despite the persistence of pathogens, however, all patients with positive sputum cultures had satisfactory clinical responses. A previous study by Blaser et al. (1983) also demonstrated persistence of the pathogens despite clearing of the patients' symptoms.
The excellent clinical response in our patients must be interpreted with some caution. The subjects were mostly young, healthy men with few underlying diseases and thus were ideal candidates for successful therapy. Even the five patients with bacteraemia had satisfactory clinical outcomes. In the aforementioned study by Blaser, however, good results were also observed in patients with underlying diseases and chronic illnesses.
The frequency of abnormalities in liver function tests in our patients was somewhat high in both treatment groups. Seven (8-7%) patients in the roxithromycin group had elevated transaminase values, which is not surprising in view of the previously reported hepatic effects of macrolide antibiotics (Gribble & Chow, 1982) . The incidence of hepatotoxicity in the cephradine group (24-3%) has not generally been reported with this agent. Despite the high incidence of such effects, they were mild and transitory and did not necessitate withdrawing any patient from the study.
Results of this study show that pneumococcal pneumonia can be effectively treated with roxithromycin in an outpatient setting. The worldwide experience with this agent was in the inpatient setting. As previously noted, even those patients with S. pneumoniae bacteraemic pneumonia in the South African miners responded well to oral therapy. This excellent response rate is undoubtedly related to the young age and excellent state of health of this population. The mortality rate seen with bacteraemic pneumococcal pneumonia is clearly related to the presence of underlying disease conditions and age (Austrian & Gold, 1964) . Patients who might be eligible for outpatient oral therapy would be those without clinical evidence of hypoxaemia or hypotension and who could be relied on to take their oral medications. Under such circumstances, agents such as roxithromycin offer a cost-effective way to treat patients with pneumococcal pneumonia.
